· Investment Strategies · 2 sources · Updated · Verified
Evvy’s $40M Series B: Catalio Backs Women’s Microbiome Data
Evvy raised a $40 million Series B led by Catalio Capital Management on September 15, 2026. Company: 100,000+ patients, 3,000 practitioners, CLIA/CLEP mNGS vaginal microbiome tests. Valuation not disclosed.
By Venture Capital Tracker Editorial
Evvy raised a $40 million Series B on September 15, 2026, led by Catalio Capital Management. Valuation was not disclosed. Company claims via TechCrunch: more than 100,000 patients served in the U.S., about 3,000 practitioners, and what it calls the only at-home CLIA- and CLEP-certified mNGS vaginal microbiome test from a single swab (TechCrunch, Fortune).
Evvy is not only selling a swab — it is trying to turn a 100k-patient dataset into the missing female-biology training set for precision medicine and fertility, with Catalio (diagnostics specialist) writing the check.
Key facts
- Company
- Evvy — women’s health diagnostics / microbiome
- Financing
- $40M Series B
- Date
- September 15, 2026
- Lead
- Catalio Capital Management (**
- Founders
- Priyanka Jain, Laine Bruzek, Pita Navarro (2021)
- Patients / clinicians (company)
- >100,000 patients; ~3,000 practitioners
- Valuation / revenue
- Not disclosed
Who uses the product — and for what job
Users: patients with vaginal health / infection / unexplained symptoms who want at-home testing; clinicians on Evvy’s network who review results and prescribe personalized care pathways.
Job: mail-in swab → mNGS sequencing in Evvy’s lab → clinician review → portal results with diagnosis, interpretation, and next steps (including prescription care when relevant). EvvyAI (launched May, per TC) translates microbiome data into guidance and routes clinical questions to humans.
Expansion: fertility / IVF-adjacent research linking vaginal microbiome to infertility, preterm birth, IVF success, and recurrent pregnancy loss — still research-stage, not a proven clinical product claim.
Why now
- Female biology is under-measured in biomedical datasets; CEO framing: you cannot build precision medicine (or AI) for women on incomplete data.
- Consumer + clinician loop at 100k patients is enough scale to pitch a research engine, not only a DTC test.
- Competitors (Juno Bio, Tiny Health, Daye — named in TC) keep the category visible; Evvy’s bet is certified mNGS + clinician network + dataset.
Why Catalio — portfolio fit
Catalio Capital Management invests in novel diagnostics. Evvy’s Series B is a textbook diagnostics thesis: regulated test (CLIA/CLEP claims) + longitudinal dataset + expansion into higher-value clinical questions (fertility).
Likely reasons Catalio led (editorial judgment):
- Diagnostics DNA — certified lab workflow, not a wellness quiz.
- Data asset — 100k patients + peer-reviewed output claims (15 publications/abstracts per CEO to TC).
- Clinical channel — 3,000 practitioners and Fortune’s note on scaling the brand into doctors’ offices.
We do not invent a /fund/catalio link. Prior investors were not fully enumerated in the TC piece we retrieved — do not invent a syndicate list.
Competitive map
| Approach | Tradeoff |
|---|---|
| Symptom-only telehealth | Fast Rx; thin biology |
| Juno Bio / Tiny Health / Daye | Same category; different test/UX claims |
| Traditional clinic cultures | Standard of care; slower at-home loop |
| Evvy mNGS + clinician network | Scale + research pitch; valuation opaque |
What is not proven
- Valuation, revenue, gross margin, or reimbursement mix.
- Clinical validity of fertility predictive claims — company says it is still compiling science.
- “Only” CLIA/CLEP mNGS positioning — company claim; verify against peers before diligence memos.
- Profitability — not disclosed.
Practical takeaway
- Founders (women’s health): Pair regulated diagnostics with a clinician network before pitching an AI layer.
- Investors: Separate DTC test economics from the research/dataset story; Catalio fit is diagnostics, not consumer brand hype.
- Clinicians / operators: Relevant if you already see unexplained recurrent BV / fertility workups and want sequenced microbiome context.
Follow Venture Capital Tracker on Google
Add VCT as a preferred source to see more of our venture-capital reporting in Google Search.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
